ArticleScientific reports2015
Genetic diversity and antimicrobial susceptibility of Nocardia species among patients with nocardiosis.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- The species distribution and antimicrobial resistance profiles of Nocardia species in China: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2023Pooled it
- Clinical Characteristics and Treatment Outcome of Central Nervous System Nocardiosis: A Systematic Review of Reported Cases.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022Pooled it
- Pooled it
- Nocardiosis: A Neglected Disease.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2020Pooled it
- Article
- Bioaerosol assessment of indoor air in hospital wards for isolation ofNew microbes and new infections · 2026Article
- Pulmonary Nocardia otitidiscaviarum in immunocompetent individuals: a case series and literature review.BMC infectious diseases · 2026Review
- Molecular mechanisms underlyingFrontiers in cellular and infection microbiology · 2026Review
- Article
- The global epidemiology, risk factors, and mortality prediction of nocardiosis: an easily missed opportunistic infection.Scientific reports · 2025Article
- Pathogenesis and treatment strategies for infectious keratitis: Exploring antibiotics, antimicrobial peptides, nanotechnology, and emerging therapies.Journal of pharmaceutical analysis · 2025Review
- Surface display of Nocardia seriolae HRP1 on Bacillus subtilis and its application as live vaccine for largemouth bass.Scientific reports · 2025Article
- Article
- Pulmonary Nocardiosis in an Immunocompetent Patient: A Case Report.Clinical case reports · 2025Article
- Genomic characteristics, virulence potential, antimicrobial resistance profiles, and phylogenetic insights into Nocardia cyriacigeorgica.Annals of clinical microbiology and antimicrobials · 2025Article
- Discovery of Novel Diagnostic Biomarkers for Common PathogenicPathogens (Basel, Switzerland) · 2025Article
- Epidemiology and Drug Resistance of Pulmonary Nocardiosis Among Tuberculosis-Suspected Patients in Guangzhou, China.Infection and drug resistance · 2025Article
- The first known case of Nocardia wallacei infection in Cyprus.GMS hygiene and infection control · 2025Article
- Multiple brain abscesses caused byFrontiers in medicine · 2025Article
- Clinical characteristics and drug resistance of Nocardia in Henan, China, 2017-2023.Annals of clinical microbiology and antimicrobials · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this multicenter study was to determine the genetic diversity and antibiotic susceptibility of clinically isolated Nocardia species. One hundred twenty-seven patients with nocardiosis were randomly selected from 5 provinces of Iran. Molecular diagnosis of Nocardia species was performed using multilocus sequence analysis of gyrase B of the β subunit of DNA topoisomerase (gyrB), and 16S rRNA and subunit A of SecA preproteintranslocase (secA1). Antimicrobial susceptibility testing was performed following the Clinical and Laboratory Standards Institute recommendations. Thirty-five N. cyriacigeorgica, 30 N. asteroides, 26 N. farcinica, 12 N. otitidiscaviarum, and 10 N. abscessus cultures were studied. All isolates were susceptible to linezolid. All isolates of N. cyriacigeorgica, N. asteroides, N. abscessus, and N. otitidiscaviarum were susceptible to trimethoprim-sulfamethoxazole, while 8% of N. farcinica isolates were resistant to this drug. All N. otitidiscaviarum isolates were highly resistant to imipenem, but N. cyriacigeorgica, N. asteroides, N. farcinica, and N. abscessus were only moderate resistant. The susceptibility patterns vary with different species of Nocardia. Resistance to trimethoprim-sulfamethoxazole in Iran is low and this drug should be first line therapy, unless drug susceptibility testing shows resistance. Linezolid also covers Nocardia well and could be a second line agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.